In addition to CD68+ cells, Lan et al. also analyzed 110 advanced stage ovarian cancers for the M2 marker CD163 and demonstrated that both progression free survival and overall survival were significantly reduced in patients with high numbers of CD163+ cells (37). Here, CD163 is linked to ovarian carcinoma.